MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD (IRM-ET)

May 22, 2025 updated by: Centre Hospitalier Universitaire, Amiens
Most studies use static visual percepts that are less representative of joint attention versus an ecological environment. This has the consequence of decreasing the perception of an interaction with a social partner, which is an essential step in achieving joint attention. The originality of this study is to improve the design of visual percepts (in the form of video) in order to mimic an ecological environment as much as possible by using MRI-ET coupling. The second originality of this study is the longitudinal exploration of the neurodevelopment of social cognition in autistic children. Studies by the Redcay and Oberwelland teams observe different activations at different ages. The hypothesis is that the perception of joint attention varies over time in people with ASD. To date, there are no studies to determine the influence of childhood neurodevelopment in autistic people on the perception of joint attention. It would be unprecedented to use the MRI-ET pairing as a tool for assessing social cognition as a function of the development of children with ASD.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

68

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
    • Picardie
      • Amiens, Picardie, France, 80054
        • Recruiting
        • CHU Amiens Picardie
        • Contact:
        • Sub-Investigator:
          • Olivier Balédent, PHD
        • Sub-Investigator:
          • Luc VANDROMME, Pr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 years to 20 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

For the group of people with Autism Spectrum Disorders (experimental group):

  • Age between 10 to 20 years old
  • Diagnosis of ASD (CARS) ≥ 30 performed at inclusion
  • IQ test evaluation (regardless of the result) performed by a trained psychologist
  • Obtaining informed oral and written consent after appropriate information
  • Obtaining informed oral and written consent from the legal guardian after information
  • Be affiliated with social security
  • No contraindication to magnetic resonance imaging

For the TD (Typical Development) group of people (control group):

  • Age between 10 to 20 years old
  • Diagnosis of ASD (CARS) <30 performed at inclusion
  • IQ test evaluation (regardless of the result) performed by a trained psychologist
  • Obtaining informed oral and written consent after appropriate information
  • Obtaining informed oral and written consent from the legal guardian after information
  • Be affiliated with social security
  • No contraindication to magnetic resonance imaging

Exclusion Criteria:

For all groups:

  • Age outside the range 10 to 20 years
  • Person with a contraindication to MRI (including claustrophobia, pace maker, neurosurgical clips, vascular clips, heart valves, ventriculoperitoneal valves, cochlear implant, neurostimulator, intraocular metal shards, joint prosthesis, etc.)
  • Person suffering from major obesity (> 140 kg) not allowing him to enter the tunnel of the MRI machine (diameter <70cm)
  • Pregnant or breastfeeding woman
  • Person under guardianship or guardianship or deprived of liberty by a judicial or administrative decision

For TD people (control group):

  • Person with psychiatric disorders such as attention disorder with or without hyperactivity, depression, bipolar disorder and schizophrenia.
  • Person with a neurological history such as epilepsy and / or neurovascular accident.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ASD
people with Autism Spectrum Disorders
Other: MRI-ET
coupled fMRI and Eye Tracking tools
Active Comparator: TD
Typical Development) group of people
Other: MRI-ET
coupled fMRI and Eye Tracking tools

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
difference of mapping IRM-ET results between both patient groups
Time Frame: one day
both patient groups are : the group of people with Autism Spectrum Disorders and Typical Development group of people
one day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire, Amiens

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 4, 2022

Primary Completion (Estimated)

June 1, 2025

Study Completion (Estimated)

June 1, 2025

Study Registration Dates

First Submitted

January 4, 2022

First Submitted That Met QC Criteria

January 4, 2022

First Posted (Actual)

January 18, 2022

Study Record Updates

Last Update Posted (Actual)

May 28, 2025

Last Update Submitted That Met QC Criteria

May 22, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • PI2021_843_0194

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe